) announced the acquisition of Tulips Dialysis Centre - a
hemodialysis center near Kuala Lumpur in Malaysia. Additionally,
the company opened two dialysis centers in the greater Kuala
Lumpur area as a joint venture with Seri Setia Group. The
financial and other terms of the acquisition as well as the joint
venture were not divulged.
Tulips Dialysis Centre is operating with 10 stations in Kota
Damansara, which is situated 20 kilometers east of Kuala Lumpur.
Meanwhile, the new centers have been opened in central Kuala
Lumpur and Selangor with 19 and 6 stations, respectively.
DaVita is slowly expanding in international markets along with
growing domestically through acquisitions and alliances. In the
first nine months of 2012, DaVita acquired 71 dialysis centers,
opened 48 centers and merged or sold 8 centers in the U.S., while
10 centers were acquired or opened outside the U.S.
DaVita has ventured into Saudi Arabia, China, India and
Germany over the past two years. The company purchased a
controlling interest in a Saudi Arabian kidney care company -
Lehbi Care, announced a joint venture with
), a China-based biotechnology company and increased its stake in
NephroLife, an India-based kidney care company, so far in 2012.
Further, in November 2011, the company acquired ExtraCorp, a
German company that owns two dialysis centers and manages two
Domestically, DaVita acquired ModernMed in January 2012 and
DSI Renal Inc. in September 2011. Additionally, the company
merged with HealthCare Partners in November 2012, which will
support and augment its primary care and specialty physician
services as well as hospital and other healthcare services.
DaVita seeks to expand its presence internationally and has
been looking for acquisition and partnership opportunities in all
major European and Asian countries. We expect that the company
will involve itself in more meaningful mergers and acquisitions
in the near future, given its strong international reputation
that provides competitive advantage in terms of global
DaVita currently carries a Zacks #3 Rank (short-term
DAVITA INC (DVA): Free Stock Analysis Report
3SBIO INC-ADS (SSRX): Free Stock Analysis
To read this article on Zacks.com click here.